Secondly, reducing IL1β in the bone inhibits expansion of the bone metastatic niche (osteoblasts, haematopoietic stem cells and endovascular cells [2]), which results in tumour cells being held in this site, preventing proliferation into overt metastases. This evidence concerns the gene IL1B and neoplasm.